Showing 2671-2680 of 19323 results for "".
Do Not Delay: Timing, Triggers, and Identifying the Right Patient for Additional Therapies in HFrEF
https://reachmd.com/programs/cme/do-not-delay-timing-triggers-and-identifying-the-right-patient-for-additional-therapies-in-hfref/54633/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Risk Stratification and Patient Selection for Perioperative ICIs
https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
https://reachmd.com/clinical-practice/cardiology/global-burden-of-stroke-and-myocardial-infarction-in-patients-at-high-risk-of-first-mace-insights-from-the-vesalius-real-study/39990/Examine global rates of stroke and MI in patients at high-risk of first MACE without prior events, as explored in the VESALIUS-REAL burden of disease study.Crohn’s & Colitis Congress: A Preview of the “Trends in IBD Care”
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/crohns-colitis-congress-a-preview-of-the-trends-in-ibd-care/10743/Amid recent advances, how can we keep IBD patients at the center of care? That’s what a session at the Crohn’s & Colitis Congress sought to answer.Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event
https://reachmd.com/programs/cme/evidence-at-a-glance-the-totality-of-evidence-impacting-clinical-decision-making-in-patients-with-hfref-without-a-recent-worsening-event/54634/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma
https://reachmd.com/programs/cme/Photobiomodulation-A-Non-Invasive-Treatment-for-Ocular-Disease-and-Trauma/35945/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, effAmesh Adalja, Infectious Disease Expert, Answers Your Latest COVID-19 Questions
https://reachmd.com/programs/public-health-call/amesh-adalja-infectious-disease-expert-answers-your-latest-covid-19-questions/11429/Is there any truth behind using hydroxychloroquine as a treatment? An infectious disease expert answers this and other FAQs.When to Begin FcRn: Initiation Criteria, Key Evidence
https://reachmd.com/programs/cme/when-to-begin-fcrn-initiation-criteria-key-evidence/54771/Explore treat-to-target strategies and FcRn inhibitor use to guide outcomes-driven management of generalized myasthenia gravis.Escalate With Intention: Stepwise, Target-Anchored Moves
https://reachmd.com/programs/cme/escalate-with-intention-stepwise-target-anchored-moves/54773/Explore treat-to-target strategies and FcRn inhibitor use to guide outcomes-driven management of generalized myasthenia gravis.The IgG Clock: Redose Using IgG Kinetics
https://reachmd.com/programs/cme/the-igg-clock-redose-using-igg-kinetics/54772/Explore treat-to-target strategies and FcRn inhibitor use to guide outcomes-driven management of generalized myasthenia gravis.